(Q39169189)

9 September 2017

title

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line (English)

1 reference

9 September 2017

1 reference

9

Naomi Kiyota

1 reference

9 September 2017

Yohei Funakoshi

1

1 reference

9 September 2017

Toru Mukohara

2

1 reference

9 September 2017

Hideo Tomioka

3

1 reference

9 September 2017

Roudy Chiminch Ekyalongo

4

1 reference

9 September 2017

Yu Kataoka

5

1 reference

9 September 2017

Yumiko Inui

6

1 reference

9 September 2017

Yuriko Kawamori

7

1 reference

9 September 2017

Masanori Toyoda

8

1 reference

9 September 2017

Yutaka Fujiwara

10

1 reference

9 September 2017

Hironobu Minami

11

1 reference

9 September 2017

publication date

9 April 2013

1 reference

Investigational New Drugs

9 September 2017

published in

1 reference

9 September 2017

volume

31

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

1158-1168

1 reference

Activation of tyrosine kinases in cancer

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

c-MET as a potential therapeutic target and biomarker in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Inhibition of the met receptor in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Control of apoptosis by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Hypoxia links ATR and p53 through replication arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma : BLCAP overexpression induces S phase arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9959-2

Oxygen induces S-phase growth arrest and increases p53 and p21(WAF1/CIP1) expression in human bronchial smooth-muscle cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23568717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-013-9959-2

1 reference

9 September 2017

1 reference